CD274 and neoplasm: A significant relationship between TMB and the objective remission rate of anti-PD-1 or anti-PD-L1 therapy has been reported for several cancers [31], and MSI, a biomarker of PD-1 blockade, is strongly associated with tumor diagnosis and immunotherapy efficacy.